{"classes":[{"categories":[{"measurements":[{"comment":"Due to a lack of events the median and confidence intervals cannot be determined.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Due to a lack of events the upper confidence interval cannot be determined.","groupId":"OG001","lowerLimit":"0.2","upperLimit":"NA","value":"0.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"Defined as the date at which the patient's objective status is first noted to be a PR or CR for patients evaluated by CT-based criteria or CMR or PMR for patients evaluated by PET-CT based criteria to the earliest date progression (documentation of disease progression \\[PMD\\] or progressive disease \\[PD\\]) is documented. The distribution of duration of response will be estimated using the method of Kaplan-Meier. The comparison of duration of response between two treatment arms will be based on the log-rank test.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may cross over to Group II at the time of disease progression.","id":"OG000","title":"Group I (Nivolumab)"},{"description":"Patients receive varlilumab IV over 90 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Group II (Varlilumab, Nivolumab)"}],"paramType":"MEDIAN","populationDescription":"All eligible and treated patients that achieve a response.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"years"}